LINC00160: A Potential Drug Target and Biomarker (G54064)

Target Name: LINC00160

NCBI ID: G54064

LINC00160

Other Name(s): Long intergenic non-protein coding RNA 160 | NCRNA00160 | C21orf52 | long intergenic non-protein coding RNA 160

LINC00160: A Potential Drug Target and Biomarker

LINC00160 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and has been shown to play a role in various diseases, including cancer. In this article, we will discuss the potential drug targets of LINC00160, its potential as a biomarker, and its current research status.

Potential Drug Targets

LINC00160 has been shown to interact with several protein kinases, including Src,FAK, and p16INK4a. These proteins are involved in various cellular processes, including cell-cycle regulation, cell survival, and angiogenesis. Therefore, LINC00160 may be a drug target for various diseases, including cancer.

In addition to its potential as a drug target, LINC00160 has also been shown to be a potential biomarker for various diseases. For example, LINC00160 has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LINC00160 has been shown to be elevated in the blood samples of patients with Alzheimer's disease, suggesting that it may be a potential biomarker for this disease as well.

Current Research

LINC00160 is currently being studied in various clinical trials as a potential drug target and biomarker. For example, a clinical trial is being conducted to evaluate the efficacy of a small molecule inhibitor of LINC00160, called LINC00160-AS-2, in treating ovarian cancer. The trial is designed to evaluate the impact of LINC00160-AS-2 on the growth and survival of ovarian cancer cells, as well as its effects on the levels of LINC00160 in the cancer cells.

Another clinical trial is being conducted to evaluate the potential of LINC00160 as a biomarker for Alzheimer's disease. The trial is designed to collect blood samples from patients with Alzheimer's disease and use them to assess the levels of LINC00160 in the blood. The researchers are also planning to use LINC00160 as a biomarker to evaluate the effectiveness of different treatments for Alzheimer's disease.

Conclusion

In conclusion, LINC00160 is a non-coding RNA molecule that has the potential to be a drug target and biomarker for various diseases. Its interaction with protein kinases and its downregulation in various cancer types make it an attractive target for drug development. Additionally, its potential as a biomarker for Alzheimer's disease makes it an important area of research. Further studies are needed to fully understand the potential of LINC00160 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 160

The "LINC00160 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00160 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets